Arndt Justus Georg Schottelius
Direttore/Membro del Consiglio presso GUBRA A/S
Patrimonio netto: 407 685 $ in data 30/04/2024
Posizioni attive di Arndt Justus Georg Schottelius
Società | Posizione | Inizio | Fine |
---|---|---|---|
GUBRA A/S | Direttore/Membro del Consiglio | 01/01/2022 | - |
Independent Dir/Board Member | 01/01/2022 | - | |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | Amministratore Delegato | 01/03/2024 | - |
Storia della carriera di Arndt Justus Georg Schottelius
Precedenti posizioni note di Arndt Justus Georg Schottelius
Società | Posizione | Inizio | Fine |
---|---|---|---|
AFFIMED N.V. | Direttore Tecnico/Scientifico/R&S | 01/04/2020 | 29/02/2024 |
MORPHOSYS AG | Corporate Officer/Principal | - | 01/03/2017 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | 01/05/2017 | - |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Arndt Justus Georg Schottelius
University of Freiburg | Doctorate Degree |
Statistiche
Distribuzione geografica
Germania | 4 |
Regno Unito | 3 |
Stati Uniti | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 6 |
Consumer Services | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
MORPHOSYS AG | Health Technology |
AFFIMED N.V. | Health Technology |
GUBRA A/S | Commercial Services |
Aziende private | 3 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Maxion Therapeutics Ltd.
Maxion Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Maxion Therapeutics is a British company that specializes in creating first-in-class and protein therapeutics for treating previously untreatable ion channel- and GPCR-driven diseases. The company was founded by John McCafferty, Aneesh Karatt-Vellatt, and is based in London, UK. The company achieves this through their revolutionary KnotBody® technology. John McCafferty has been the CEO since incorporation. | Health Technology |